SOURCE: TSRL, Inc.

TSRL, Inc.

February 02, 2011 14:41 ET

TSRL, Inc. Announces NIH - NIAID Phase II SBIR Grant Award

ANN ARBOR, MI--(Marketwire - February 2, 2011) - Therapeutic Systems Research Laboratories (TSRL), Inc. announces the award of a Phase II SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). TSRL will receive up to $2.6 million over the next 3 years, further supporting the development of the company's oral influenza prodrug program. In addition, TSRL will be accessing NIAID's preclinical services for the initial scale up of their lead candidates, TSR-026 and TSR-462. The company is planning on using these funds in addition to funds from the therapeutic tax credit grants received at the end of 2010 to advance their lead influenza therapeutics candidate to IND.

Contact Information

  • For additional information contact
    Dr. Elke Lipka
    Vice President of Business Development
    734 663-4233 x 236
    Email Contact